Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Ionis Pharmaceuticals
IONS
Ionis Pharmaceuticals
Aging Demographic Trends And Precision Medicine Will Power Blockbuster Launches
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 26 Analysts
Published
04 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$82.61
48.6% undervalued
intrinsic discount
16 Aug
US$42.48
Loading
1Y
-10.2%
7D
2.6%
Author's Valuation
US$82.6
48.6% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$82.6
48.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-550m
2b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.8b
Earnings US$181.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
19.40%
Biotech revenue growth rate
12.78%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.09%
Calculation
US$181.02m
Earnings '28
x
109.30x
PE Ratio '28
=
US$19.79b
Market Cap '28
US$19.79b
Market Cap '28
/
195.26m
No. shares '28
=
US$101.33
Share Price '28
US$101.33
Share Price '28
Discounted to 2025 @ 7.09% p.a.
=
US$82.50
Fair Value '25